Aridis Pharmaceuticals said that “an undisclosed pharmaceutical company” has agreed to pay $6.5 million plus annual royalty payments for Aridis’ AR-501 nebulized gallium for the treatment of chronic lung infections in patients with cystic fibrosis. Aridis said that it expects to receive 50% of the upfront payment by the end of the first quarter of 2025 and the other 50% by the end of the second quarter, at which point the new partner will acquire “exclusive ownership of AR-501.”
In March 2023, Aridis announced that a Phase 2a trial of AR-501 in CF patients with P. aeruginosa lung infections had met its primary and secondary endpoints. According to the new announcement, “The positive clinical trial data also facilitated the filing for non-dilutive grant funding support from governmental sources and nongovernmental organizations (NGOs), which we intend to explore.”
Read the Aridis Pharmaceuticals press release.
